Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006;71:713–21.Google Scholar
Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–27.Google Scholar
Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 2012;52:809–18.Google Scholar
US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed: 12 September 2018.
European Medicines Agency (EMA) (2016) Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) model and simulation. Available from: http://www.ema.europa.eu/ema/. Accessed: 12 September 2018.
US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Guidance for industry: physiologically based pharmacokinetic analysis. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed: 12 September 2018.
US Food and Drug Administration. Drugs@FDA: FDA approved drug products: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed: 12 September 2018.
Sato M, Ochiai Y, Kijima S, Nagai N, Ando Y, Shikano M, et al. Quantitative modeling and simulation in PMDA: a Japanese regulatory perspective. CPT Pharmacometrics Syst Pharmacol 2017;6:413–5.Google Scholar
Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, et al. WARFARIN-FLUCONAZOLE II: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422–8.Google Scholar
Wagner C, Pan Y, Hsu V, Sinha V, Zhao P. Predicting the effect of CYP3A inducers on the pharmacokinetics of substrate drugs using physiologically based pharmacokinetic (PBPK) modeling: an analysis of PBPK submissions to the US FDA. Clin Pharmacokinet 2016;55:475–83.Google Scholar
Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004;34:151–78.Google Scholar
Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 2011;51:1644–54.Google Scholar
Rowland Yeo K, Rostami-Hodjegan A, Tucker GT. Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 2004;57:687–8.Google Scholar
Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007;24:918–33.Google Scholar
Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007;8:676–84.Google Scholar
Camenisch G, Umehara K. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharm Drug Dispos 2012;33:179–94.Google Scholar
Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole I: inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996;24:414–21.Google Scholar
Neal JM, Kunze KL, Levy RH, O’Reilly RA, Trager WF. Ki iv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 2003;31:1043–48.Google Scholar
Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol 2011;51:561–74.Google Scholar
Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12:327–33.Google Scholar
Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420–5.Google Scholar
Shon JH, Yoon YR, Kim KA, Lim YC, Lee KY, Park JY, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002;12:111–9.Google Scholar
Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos 2011;39:170–3.Google Scholar
Camenisch G, Riede J, Kunze A, Huwyler J, Poller B, Umehara K. The extended clearance model and its use for the interpretation of hepatobiliary elimination data. ADMET & DMPK 2015;3:1–14.Google Scholar
Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002;30:831–7.Google Scholar
Shi JG, Fraczkiewicz G, Williams WV, Yeleswaram S. Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. Clin Pharmacol Ther 2015;97:177–85.Google Scholar
Kirby BJ, Collier AC, Kharasch ED, Dixit V, Desai P, Whittington D, et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 2011;39:2329–37.Google Scholar
Vormfelde SV, Brockmöller J, Bauer S, Herchenhein P, Kuon J, Meineke I, et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther 2009;86:54–61.Google Scholar
Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 2013;34:141–54.Google Scholar
About the article
Published Online: 2019-05-30
Author contributions: Participated in research designs: Umehara, Huth, Jin, and Schiller. Conducted experiments: Umehara, Huth, Jin, and Schiller. Performed data analysis: Umehara, Huth, Jin, and Schiller. Wrote or contributed to the writing of the manuscript: Umehara, Huth, Jin, Schiller, Aslanis, Heimbach, and He. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Ethical approval: This PBPK study does not require ethics approval; for the cited clinical studies ethical approval has been granted.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.